TNFRSF9 and head and neck squamous cell carcinoma: In particular, preclinical studies suggest that the inhibition of MDSCs and the reduction in Tregs enhance immunotherapy in HNSCC [63, 64], supporting the clinical value of CD137+Treg and LOX-1+PMN-MDSC cells and their target as therapeutic approach.